Dr. Berry is an Associate Professor of Ophthalmology, Clinical Scholar, and holds the Berle and Lucy Adams Chair in Cancer Research at the University of Southern California Roski Eye Institute. She is also the Vice Chair for Academic Affairs for the Department of Surgery and Director of Ocular Oncology at the Roski Eye Institute & Children’s Hospital Los Angeles.

1. Please share with us your background.

I was born and raised in Oshkosh, Wisconsin (home of the Oshkosh B’Gosh overalls)—a relatively small, Midwestern town. I was the first in my family to attend college and headed to Boston to start at Harvard College. I think I was always a bit of an adventurer and a city girl at heart, and I quickly felt at home in my new city. I studied biochemistry with a minor in Spanish. I stayed in Boston for Harvard Medical School, where I developed an interest in international health and surgical missions. This led me to Africa at the end of my first year, where I witnessed my first ocular surgery. I was quickly sold on the gift of restoring vision and decided to pursue ophthalmology.

Desiring another year in a bigger city, I spent my intern year at Memorial Sloan Kettering in New York City. While there, my real passion was ignited, as I was privileged to rotate on the ocular oncology service with David Abramson, MD, and take care of adults with melanoma and children with retinoblastoma. I was fascinated by the ability to look into an eye and see cancer forming and regressing with therapy. I remember telling Dr. Abramson that I wanted to focus on ocular oncology, and he said, “Well, you better find Dr. Linn Murphree in Los Angeles.” I did just that: I finished my ophthalmology residency at LAC + USC Medical Center, which was a formative part of my surgical training. I then completed a fellowship in pediatric and adult ocular oncology at the Children’s Hospital Los Angeles and the University of Southern California as Dr. Murphree’s last fellow, with a focus on retinoblastoma and uveal melanoma.

2. What is the focus of your recent research?

My research involves the development of a liquid biopsy from the aqueous humor for ocular tumors— specifically retinoblastoma—and is supported by the National Cancer Institute. Although tumor biopsy is the diagnostic norm for most malignancies, direct biopsy is contraindicated in retinoblastoma due to the risk of extraocular tumor spread. Thus, molecular and genetic analyses of retinoblastoma tumors is only available from enucleated eyes. Because of this, no tumor-derived molecular markers exist for diagnosis, prognosis, or predictive medicine for affected children.

However, in 2017, this paradigm changed when we demonstrated for the first time that the aqueous humor is a rich source of tumor-derived cell-free DNA. Our initial proof-of-principle manuscript was published in 2017, and in the past 5 years we have published 10 papers describing the application and utility of the aqueous as a liquid biopsy. Recently, we used this novel liquid biopsy platform on 50 eyes with more than 2 years of follow-up to identify a tumor-derived biomarker—gain of chromosome 6p—that is highly predictive of aggressive tumor behavior, leading to intraocular tumor relapse.

We hope in the very near future that this will be a clinically available test that is validated for use to predict which patients will respond to therapy—and maybe even which therapies (!) will be most effective for these young retinoblastoma patients.

3. What has your experience been collaborating with industry?

As a translational scientist, I respect the role of industry collaborations in ushering in some of the most impactful bench science to the bedside. I have been privileged to help consult on a few such products. I am also grateful for industry support in academic and research endeavors and the broader educational mission.

4. In your opinion, how is the role of women in ophthalmology evolving?

Women are knocking it out of the park in so many professions—ophthalmology included. More women than ever are attending medical school and entering every medical and surgical subspecialty. The ability to be a surgeon, a wife, a mom, and a human is now part of the normal dialogue in medicine. The thought that women have to give up on family or can’t be doctors—or surgeons—is outdated. However, that is not to say that it’s easy or even that our culture is 100% adapted to it. Women still manage the majority of child care and home care, they are more likely to choose to go part time after having kids (which maybe sometimes feels like the only choice!), and there is still substantial room for growth in the top echelons of leadership. When women are represented, we all benefit and grow. We need more women as chairs, deans, editors of journals, and CEOs and generally more represented in leadership. As female leadership grows, I suspect (and hope) that there will be subtle cultural shifts that respect and acknowledge all the contributions women make in the workplace, which might need to be measured outside of just relative value units.

5. What hurdles do you feel women in health care still face?

Community perception of women in medicine hasn’t quite caught up to the professional culture. I don’t know of a single female surgeon who hasn’t had the experience of being assumed that they are not the surgeon or being asked if they are going to stop working after having children. This can be frustrating, but it also shows the wonderful growth that has been made in recent years. With continued campaigns like “I Look Like a Surgeon,” these perceptions will grow and evolve as well.

6. What advice can you offer to young female ophthalmologists who are still in training or just beginning their careers?

Find your passion! My number-one recommendation is to listen to what you love. In training, pay attention to the days that fly by because you are fascinated by the disease being treated. Medicine is a wonderful field. I feel so useful and impactful every day. But it is also hard. It takes a lot of sacrifice and long hours. Holding the care of other humans in your hands is demanding and daunting, and it can be a lot to carry. It is why burnout is such a major topic these days. To me, the real remedy to burnout is doing what you love so that is refills your cup. I can’t tell you the number of times during the pandemic that I have felt exhausted—only to have a day in the OR with my retinoblastoma kids that, although hard, leaves me rejuvenated. I find this happens only when passion and purpose combine. Doing what you love helps everything else fall into place.

7. Can you propose a unique or creative idea that may help women in ophthalmic practices?

Flexibility in practice. Two kids in, I have found that what I most need and appreciate in my practice is flexibility. This has been a real game-changer for me during the pandemic. Being able to work from home on academic days has helped so much. Not only do I save 2 hours in LA traffic, but I am able to work home and still be present if something happens with the kids. A few times when they were sick, this was critical. My clinical days are inflexible in general, but I have research and administrative days that give me the flexibility I need in my week to focus on all the work needed to fulfill my many roles. This allows me to attend my daughters’ doctor appointments and sometimes even do school pickup and dropoff. Flexibility also allows me to work at 3 AM or 3 PM or 10 PM, as I am not stuck on a rigid 8 AM to 5 PM schedule. Because I have flexible days, I don’t get as frustrated when I am in clinic late or when an emergency in the OR causes me to miss bedtime. Ultimately, I know that sometimes I can move things to be present at home and sometimes I do the same in the hospital, and it works out. I encourage women to look for flexibility—whether that means being able to start early or end late in clinic, work from home occasionally, or structure various roles (surgeon, clinician, researcher, administrator) for a more flexible schedule—and to seek out employers that support this flexibility.

---

PUBLISHED WORKS

• Kaliki S, Shields C, Cassoux N, Munier F, Chantada G, Grossniklaus H, Yoshikawa H, Ido F, Berry JL, et al. Defining high-risk retinoblastoma: a multicenter global survey. JAMA Ophthalmol. 2022;140(1):30-36.
• Shen A, Haghighi A, Liang T, Lee O, Gange W, DeBoer C, Akhter M, Saber M, Patel V, Berry JL, Gokoffski K. Metastatic neuroendocrine tumors mimicking as primary ocular disease. Am J Ophthalmol Case Rep. 2022;26:101425.
• Peng C, Im D, Sirivolu S, Reiser B, Nagiel A, Neviani P, Xu L, Berry JL. Single vesicle analysis of aqueous humor in pediatric ocular diseases reveals eye specific CD63-dominant subpopulation. J Ex Bio. 2022. Accepted.
• Lloyd P, Westcott M, Kaliki S, Ji X, Zhou Y, Rashid R, Sultana S, Sherief ST, Cassoux N, Coronado RYD, Leon JLG, Lopez AMZ, Polyakov VG, Ushakova TL, Roy SR, Ahmad Al Harby LA, Berry JL, et al. The role of maternal age & birth order on the development of unilateral and bilateral retinoblastoma: a multicentre study [published online March 31, 2022]. Eye. doi:10.1038/s41433-022-01992-w
• Berry JL. Staging and grouping of retinoblastoma. In: Albert DM, Miller JW, Azar DT, Young LH, eds. Albert and Jakobiec’s Principles and Practices of Ophthalmology. 4th ed. Springer; 2021:1-13.
• Polski A, Berry JL, Gombos D. Ophthalmological manifestations of systemic neoplasia and its treatment. In: Albert DM, Miller JW, Azar DT, Young LH, eds. Albert and Jakobiec’s Principles and Practices of Ophthalmology. 4th ed. Springer; 2021:2-13.
• Wong EY, Shah S, Berry JL. Oculodermal melanosis. In: Nariani A, Shields, eds. Ocular Manifestations of Systemic Disease. 2021. In press.
• Kim ME, White A, Gonzalez M, Berry JL. Specialty interest groups with global presence. In: Chawla, Aronow M, eds. Global Perspectives in Ocular Oncology. 2021. In press.
• Alexander JL, Wei L, Palmer J, Darras A, Levin MA, Berry JL, Ludeman E. A systematic review of ultrasound biomicroscopy use in pediatric ophthalmology. Eye (Lond). 2021;35:265-276.
• Berry JL, Munier F, Gallie BL, et al. Response criteria for intraocular retinoblastoma: RB-RECIST. Pediatr Blood Cancer. 2021;e28964.
• Xu L, Kim ME, Polski A, Prabakar RK, Shen L, Peng C, Reid M, Chevez-Barrios P, Kim JW, Shah R, Jubran R, Kuhn P, Cobrinik D, Biegel JA, Gai X, Hicks J, Berry JL. Establishing clinical utility of ctDNA analysis for diagnosis, prognosis and treatment monitoring for retinoblastoma: the aqueous humor liquid biopsy. Cancers. 2021;13:1281.
• Kaliki S, Ji X, Sultana S, et al. Lag time between onset of first symptom and treatment of retinoblastoma: an international collaborative study of 692 patients from 10 countries. Cancers. 2021;13(8):1956.
• Huang VP, Kim ME, Mohan S, Daskivich L, Berry JL. The utility of recycled eyeglasses: a pilot study at the Los Angeles County Department of Health Services. Int J Med Students. 2021;9(1):37-40.
• Joh S, Kim ME, Reilly M, Zhou SY, Kim JW, Jennelle RL, Berry JL. Outpatient ocular brachytherapy: the USC experience. Adv Radiat Oncol. 2021;6(5):100737.
• Kim ME, Polski A, Xu L, Prabakar R, Peng C, Reid MW, Shah R, Kuhn P, Cobrinik D, Hicks J, Berry JL. Comprehensive somatic copy number analysis using the aqueous humor liquid biopsy for retinoblastoma. Cancers. 2021;13:3340.
• Fabian ID, Khetan V, Stacey A, Foster A, Ademola-Popoola D, Berry JL, et al. Sex, gender, and retinoblastoma: analysis of 4351 patients from 153 countries [published online July 16, 2021]. Eye (Lond). doi:10.1038/s41433-021-01675-y
• Wong E, Xu L, Shen L, Kim ME, Polski A, Prabakar RK, Shah R, Jubran R, Kim JW, Biegel J, Gai X, Kuhn P, Hicks J, Berry JL. Inter-eye genomic heterogeneity in bilateral retinoblastoma via aqueous humor liquid biopsy. NPJ Precis Oncol. 2021;5(1):73.
• Tomar AS, Finger P, Gallie B, Kivela T, Mallipatna A, Zhang C, Zhao J, Wilson M, Brennan R, Burgess M, Kim JW, Berry JL, et al. Retinoblastoma seeds: impact on American Joint Committee on Cancer clinical staging [published online August 2, 2021]. Br J Ophthalmol. doi:10.1136/bjophthalmol-2021-318892
• Kim ME, Xu L, Prabakar RK, Shen L, Peng C, Kuhn P, Gai X, Hicks J, Berry JL. Aqueous humor as a liquid biopsy for retinoblastoma: clear corneal paracentesis and genomic analysis. J Vis Exp. 2021;7:175.
• Fabian ID, Stacey AW, Bowman R, et al, and the Global Retinoblastoma Study Group. Retinoblastoma management during the COVID-19 pandemic: a report by the Global Retinoblastoma Study Group including 194 centers from 94 countries. Pediatr Blood Cancer. 2021:68(1):e28584.
• Randhawa JK, Kim ME, Polski A, Reid MW, Mascarenhas K, Brown B, Fabian ID, … Berry JL. The effects of breastfeeding on retinoblastoma development: results from an international multi-center retinoblastoma survey. Cancers. 2021;13(19):4773.
• O’Fee JR, Polski A, Rayess N, Zhou S, Jennelle R, Berry JL. The impactof intraoperative ultrasound on operative time during plaque brachytherapy insertion for uveal melanoma. Am Med Stud Res J. 2021. Accepted.
• Kim JW, Shah S, Tamrazi B, Green S, O’Fee J, Berry JL. Tumor size criteria for group D and E eyes in the International Classification System for Retinoblastoma: effects on rates of globe salvage and high-risk histopathologic features. Acta Ophthalmologica. 2020;98(1):e121-125.
• Polski A, Xu L, Prabakar RK, Kim JW, Jubran R, Shah R, Kuhn P, Cobrinik D, Hicks J, Berry JL. Cell-free DNA tumor fraction in the aqueous humor is associated with therapeutic response in retinoblastoma patients. Trans Vis Sci Tech. 2020;9(10):30.
• Berry D, Seider M, Stinnett S, Mruthyunjaya P, Schefler AC, and the Ocular Oncology Study Consortium. Correlation of gene expression profile status and American Joint Commission on Cancer stage in uveal melanoma. Retina. 2020;40(2):214-224.
• Berry JL, Xu L, Polski A, Jubran R, Kuhn P, Kim JW, Hicks J. Aqueous humor is superior to blood as a liquid biopsy for retinoblastoma. Ophthalmology. 2020;127(4):552-554.
• Seider M, Berry D, Stinnett S, Mruthyunjaya P, Schefler AC, and the Ocular Oncology Study Consortium. Multi-center analysis of intraocular biopsy technique and outcomes for uveal melanoma: Ocular Oncology Study Consortium Report 4. Graefes Arch Clin Exp Ophthalmol. 2020;258(2):427-435.
• Lu J, Chang J, Berry JL, In GK, Zhang-Nunes S. Clinical update on checkpoint inhibitor therapy for conjunctival and eyelid melanoma. Int Ophthalmol Clin. 2020;60(2):77-89.
• Binder C, Mruthyunjaya P, Schefler A, and the Ocular Oncology Study Consortium. Practice patterns for the treatment of uveal melanoma with iodine-125 plaque brachytherapy: Ocular Oncology Study Consortium Report 5. Ocul Oncol Pathol. 2020;6:210-218.
• Global Retinoblastoma Study Group. Global retinoblastoma presentation: analysis by national income level. JAMA Oncol. 2020;6(5):1-12.
• Xu L, Polski A, Prabakar RK, Reid MW, Chevez-Barrios P, Jubran R, Kim JW, Kuhn P, Cobrinik D, Hicks J, Berry JL. Chromosome 6p amplification in aqueous humor cell-free DNA is a prognostic biomarker for retinoblastoma ocular survival. Mol Cancer Res. 2020;18(8):1166-1175.
• Polski A, Xu L, Prabakar RK, Gai X, Kim JW, Shah R, Jubran R, Kuhn P, Cobrinik D, Hicks J, Berry JL. Variability in retinoblastoma genome stability is driven by age and not heritability. Genes Chromosomes Cancer. 2020;59(10):584-590.
• Berry JL, Kim ME, Pefkianaki M, et al. Intravitreal melphalan for retinoblastoma: the impact of toxicity on recurrence and ultimate globe salvage. Ocul Oncol Pathol. 2020;6(6):388-394.
• Green KM, Toy BC, Ashimatey BS, Mustafi D, Jennelle R, Astrahan MA, Zhongdi C, Wang RK, Kim JW, Berry JL, Kashani AH. Quantifying subclinical and longitudinal microvascular changes following episcleral plaque brachytherapy (EPB) using spectral-domain OCT angiography. J Vitreoretin Dis. 2020:4(6):499-508.
• Xu L, Shen L, Polski A, Prabakar RK, Reid MW, Shah R, Jubran R, Kim JW, Biegel J, Kuhn P, Cobrinik D, Hicks J, Gai X, Berry JL. Simultaneous identification of clinically relevantRB1mutations and somatic copy number alterations in the aqueous humor of retinoblastoma eyes. Ophthalmol Genet. 2020;41(6):526-532.
• Berry JL. Changing trends in retinoblastoma treatment and what is in store for the future. In: Khetan V, ed. Intraocular Tumors. Springer; 2020:29-47.
• Berry JL, O’Brien J. Retinoblastoma. In: Hartnett ME, ed. Pediatric Retina. 3rd ed. Lippincott Williams & Wilkins; 2020.
• Polski A, Berry JL, Randolph. Retinoblastoma and the RB1 cancer syndrome. Emery and Rimoin’s Principles and Practice of Medical Genetics. Elsevier; 2020.
• Kim JW, Berry JL, Murphree AL. Retinoblastoma. Ryan’s Retina. Elsevier; 2020.
• Berry JL. Angiomatous tumors. In: Syed NA, ed. Basic Clinical & Science Course (BCSC) Section 4: Ophthalmic Pathology and Intraocular Tumors. AAO; 2020.
• Berry JL. Retinoblastoma. In: Syed NA, ed. Basic Clinical & Science Course (BCSC) Section 4: Ophthalmic Pathology and Intraocular Tumors. AAO; 2020.
• Berry JL. Ocular involvement in systemic malignancies. In: Syed NA, ed. Basic Clinical & Science Course (BCSC) Section 4: Ophthalmic Pathology and Intraocular Tumors. AAO; 2020.
• Lu J, Francis J, Dunkel I, Shields CL, Yu M, Berry JL, et al. Metastases and death rates after primary enucleation of unilateral retinoblastoma in the United States 2007-2017. Br J Ophthalmol. 2019;103(9):1272-1277.
• Berry D, Seider M, Stinnett S, Mruthyunjaya P, Schefler AC, and the Ocular Oncology Study Consortium. Relationship of clinical features and baseline tumor size with gene expression profile status in uveal melanoma: a multi-institutional study. Retina. 2019;1-11.
• Berry JL, Lee R, Patel L, Le BA, O’Fee J, Jubran R, Kim JW. Posterior vitreous detachment and the associated risk of retinal toxicity with intravitreal melphalan for retinoblastoma. Ocul Oncol Pathol. 2019;5(4):238-244.
• Narala R, Kim JW, Lang P, Le BA, Hendargo H, Branco D, Berry JL. Changes in central retinal thickness on spectral domain optical coherence tomography pre- and post-intravitreal Melphalan for retinoblastoma seeding. Ophthalmol Retina. 2019;3(3):288-289.
• Gudiseva H, Berry JL, Polski A, Tummina S, O’Brien JM. Next generation technologies and strategies for the management of retinoblastoma. Genes. 2019;10(12):1032.
• Berry JL, Polski A, Cavenee WK, Dryja TP, Murphree AL, Gallie BL. The RB1 story: characterization and cloning of the first tumor suppressor gene. Genes. 2019;10(11):879.
• Polski A, Saber M, Kim JW, Berry JL. Extending far and wide: the role of biopsy and staging in the management of ocular surface squamous neoplasia. Clin Experiment Ophthalmol. 2019;47(2):193-200.
• Shah S, Kogachi K, Correa Z, Schefler A, Aronow M, Callejo S, Cebulla C, Ghafoori S, Francis J, Lally S, McCannel T, Paton K, Phan I, Pointdujour-Lim R, Ramasubramanian A, Rath P, Shields C, Skalet A, Wills J, Jennelle R, Berry JL. Trends in radiation practices for female ocular oncologists in North America: a collaborative study of the International Society of Ocular Oncology. Ocul Oncol Pathol. 2019;5(1):54-59.
• Mafi JN, Godoy-Travieso P, Wei E, Anders M, Amaya R, Carrillo C, Berry JL, et al. Evaluation of a choosing wisely initiative to reduce low-value preoperative care for patients undergoing cataract surgery at a large safety net health system. JAMA Internal Medicine. 2019;179(5):648-657.
• Nguyen S, Jones M, Olch A, Kim JW, Berry JL, Chang E, Wong KE. Lens dose-response prediction modeling and cataract incidence in retinoblastoma patients after lens-sparing or whole-eye radiotherapy. Int J Radiat Oncol Biol Phys. 2019;103(5):1143-1150.
• Berry JL, Kogachi K, Murphree AL, Jubran R, Kim JW. A review of recurrent retinoblastoma: Children’s Hospital Los Angeles classification & treatment guidelines. Int Ophthalmol Clin. 2019;59(2):65-75.
• Kim ME, Shah S, Zolfaghari E, Jubran R, Reid M, Kim JW, Berry JL. An intraocular pressure predictive of high-risk histopathologic features in group E retinoblastoma eyes. Int Ophthalmol Clin. 2019;59(2):77-86.
• Ghiam BK, Xu L, Berry JL. Aqueous humor markers in retinoblastoma, a review. Transl Vis Sci Technol. 2019;8(2):13.
• Berry JL, Murphree AL. Retinoblastoma staging and grouping. In: Berry JL, Kim JW, Singh AD, Damato BE, eds. Clinical Ophthalmic Oncology. Springer; 2019:27-38.
• Berry JL, Murphree AL. Retinoblastoma focal therapy. In: Berry JL, Kim JW, Singh AD, Damato BE, eds. Clinical Ophthalmic Oncology. Springer; 2019:141-148.
• Wong KE, Berry JL, Kim JW. Retinoblastoma external beam radiation. In: Berry JL, Kim JW, Singh AD, Damato BE, eds. Clinical Ophthalmic Oncology. Springer; 2019:193-204.
• Ghiam BK, Ghaffarieh A, Mathews A, Saber M, Berry JL. Specimen processing for ocular tumors. In: Yanoff M, ed. Advances in Ophthalmology and Optometry. Vol 4. Elsevier; 2019:129-145.
• Patel R, Le A, Jennelle R, Berry JL. Evidence for dose de-escalation in brachytherapy treatment for choroidal melanoma. In: Yanoff M, ed. Advances in Ophthalmology and Optometry. Vol 4. Elsevier; 2019:101-128
• Berry JL. Love what you do. In: Shome D, Govil Bhasker A, eds. Dear People, with Love and Care, Your Doctors. Bloomsbury; 2019;69-70.
• Berry JL. Angiomatous tumors. In: Syed NA, ed. Basic Clinical & Science Course (BCSC) Section 4: Ophthalmic Pathology and Intraocular Tumors. AAO; 2019:281-288.
• Berry JL. Retinoblastoma. In: Syed NA, ed. Basic Clinical & Science Course (BCSC) Section 4: Ophthalmic Pathology and Intraocular Tumors. AAO; 2019:289-302.
• Berry JL. Ocular Involvement in Systemic Malignancies. In: Syed NA, ed. Basic Clinical & Science Course (BCSC) Section 4: Ophthalmic Pathology and Intraocular Tumors. AAO; 2019:303-316.
• Damato B, Afshar A, Jennelle R, Berry JL, Kim JW. Brachytherapy. In: Ichhpujani P, Spaeth GL, Yanoff M, eds. Expert Techniques of Ophthalmic Surgery. Jaypee; 2019:760-769.
• Ghiam BK, Xu L, Berry JL. Aqueous humor biomarkers for retinoblastoma, a pediatric ocular malignancy. Clinical Laboratory International. May 2019.
• Storey P, Olmos de Koo L, Berry JL. Bilateral choroidal osteomas in Rosai-Dorfman disease. Journal of VitreoRetinal Diseases. 2019;3(2):114-117.
• Berry JL, Kogachi K, Jubran R, Kim JW. Loss of fundus view as an indication for secondary enucleation in retinoblastoma. Pediatr Blood Cancer. 2018;65(4):e26908.
• Zolfaghari E, Kim JW, Krishnan S, Chévez-Barrios P, Berry JL. Atypical retinal pigment epithelial hyperplasia and glial proliferation masquerading as progressive recurrent retinoblastoma: a case report review and clinicopathologic correlation. Ocul Oncol Pathol. 2018;4:116-121.
• Kim JW, Jacobson B, Ko M, Lee DK, Jubran RJ, Berry JL. Three presentations of CNS disease in patients with intraocular retinoblastoma at tertiary medical center in the United States. Ophthalmic Genet. 2018;39(1):115-119.
• Shih GC, Le BA, Correa ZM, Sibug-Saber ME, Kim JW, Berry JL. Late apical recurrence of choroidal melanoma 10 years after successful brachytherapy. Ocul Oncol Pathol. 2018;4:225-229.
• Lang P, Kim JW, McGovern K, Reid M, Subramanian K, Murphree AL, Berry JL. Porous orbital implants after enucleation in retinoblastoma patients: indications and complications. Orbit. 2018;20:1-6.
• Bellerive C, Berry JL, Polski A, Singh AS. Conjunctival squamous neoplasia: staging & initial treatment. Cornea. 2018;37(10):1287-1291.
• Berry JL, Shah S, Kim F, Jubran R, Kim JW. Integrated treatment during the intravitreal Melphalan era: concurrent intravitreal Melphalan and systemic chemoreduction. Ocul Oncol Pathol. 2018;4(6):335-340.
• Berry JL, Xu L, Kooi I, et al. Genomic cfDNA analysis of aqueous humor in retinoblastoma predicts eye salvage: the surrogate tumor biopsy for retinoblastoma. Mol Cancer Res. 2018;16(11):1701-1712.
• Le BA, Kim JW, Deng H, Rayess N, Jennelle RL, Zhou SY, Astrahan MA, Berry JL. Outcomes of choroidal melanomas treated with eye physics plaques: 25-year review. Brachytherapy. 2018;17(6):981-989.
• Kogachi K, Kim JW, Green S, Jubran R, Berry JL. Lurking below: massive choroidal invasion under a calcified tumor after attempted conservative therapy for retinoblastoma. Ophthalmic Genet. 2018;39(5):653-657.
• Narala R, Kogachi K, Berry JL. Localized toxicity from intra-ocular chemotherapy in retinoblastoma. In: Yanoff M, ed. Advances in Ophthalmology and Optometry. Vol 3. Elsevier; 2018:101-113.
• Polski A, Greer C, Berry JL. Topical chemotherapy and the evolving role of the biopsy in OSSN. In: Yanoff M, ed. Advances in Ophthalmology and Optometry. Vol 3. Elsevier; 2018:115-137.
• Patel R, Le A, Jennelle R, Berry JL. Evidence for dose de-escalation in brachytherapy treatment for choroidal melanoma. In: Yanoff M, ed. Advances in Ophthalmology and Optometry. Vol 3. Elsevier; 2018:139-153.
• Jennelle R, Berry JL, Kim JW. Uveal melanoma. In: Chang EL, ed. Adult CNS Radiation Oncology. Springer; 2018:243-258.
• Do B, Berry JL, Rodger D. Masquerade syndromes. In: Rao NA, Rodger DC, Schallhorn J, eds. Posterior Uveitis: Advances in Imaging and Treatment. Springer; 2018:141-154.
• Augsburger JJ, Correa Z, Berry JL. Malignant intraocular neoplasms. In: Yanoff M, Duker JS, eds. Ophthalmology. 5th ed. Elsevier; 2018:795-826.
• Shah S, Koban Y, Le B, Bechtold M, Zolfaghari, Kim JW, Berry JL. Iris hypoplasia as the presenting sign of retinoblastoma in a child with a 13q deletion. J Pediatr Ophthalmol Strabismus. 2018;55:e10-13.
• Shah S, Berry JL. Pearls for treating retinoblastoma. US Ophthalmic Review. 2018;11(2):79-80.
• Aziz HA, Kim JW, Munier FL, Berry JL. Acute hemorrhagic retinopathy following intravitreal Melphalan injection for retinoblastoma: a report of 2 cases and technique modifications to enhance prevention of retinal toxicity. Ocul Oncol Pathol. 2017;3(1):34-40.
• Berry JL, Kogachi K, Aziz HA, et al. Risk of metastasis and orbital recurrence in advanced retinoblastoma eyes treated with systemic chemoreduction versus primary enucleation. Pediatr Blood Cancer. 2017;64(4).
• Kim JW, Aziz HA, McGovern K, Zolfaghari E, Jubran R, Berry JL. Treatment outcomes of focal laser consolidation during chemoreduction for group B retinoblastoma. Ophthalmol Retina. 2017;1(5):361-368.
• Berry JL, Anulao K, Kim JW. Optical coherence imaging of large spherical seed in retinoblastoma. Ophthalmology. 2017;124(8):1208.
• Berry JL, Zolfaghari E, Chen A, Jubran R, Kim JW. Optic nerve obscuration in retinoblastoma: a risk factor for optic nerve invasion? Ocul Oncol Pathol. 2017;3(4):283-291.
• Mruthyunjaya P, Seider M, Stinnett, and the Ocular Oncology Study Consortium. Association between tumor regression rate gene expression profile after Iodine-125 plaque radiotherapy for uveal melanoma. Ophthalmology. 2017;124(10):1532-1539.
• Scelfo C, Francis J, Khetan V, Jenkins T, Marr B, Abramson DH, Shields C, Peter J, Munier F, Berry JL, et al. An international survey of classification and treatment choices for group D retinoblastoma. Int J Ophthalmol. 2017;10(6):961-967.
• Berry JL, Bechtold M, Shah S, et al. Not all seeds are created equal: seed classification is predictive of outcomes in retinoblastoma. Ophthalmology. 2017;124(12):1817-1825.
• Kim JW, Madi I, Lee R, Zolfaghari E, Jubran R, Lee TC, Murphree AL, Berry JL. Clinical significance of optic nerve enhancement on magnetic resonance imaging in enucleated retinoblastoma patients. Ophthalmol Retina. 2017;1(5):369-374.
• Mustafi D, Damato B, Berry JL. Unilateral multifocal choroidal melanoma. Ocul Oncol Pathol. 2017;4(1):48-51.
• Berry JL, Shah S, Bechtold M, Zolfaghari E, Jubran R, Kim JW. Long-term Outcomes of group D retinoblastoma eyes during the intravitreal melphalan era. Pediatr Blood Cancer. 2017;64(12).
• Kim JW, Jacobson B, Zolfaghari E, Ferrario A, Chevez-Barrios P, Berry JL, et al. Rabbit model of ocular indirect photodynamic therapy using a retinoblastoma xenograft. Graefes Arch Clin Exp Ophthalmol. 2017;255(12):2363-2373.
• Berry JL, Xu L, Murphree AL, et al. Potential of aqueous humor as a surrogate biopsy for retinoblastoma. JAMA Ophthalmol. 2017;135(11):1221-1230.
• Francis JH, Abramson DH, Ji X, Shields C, Teixeira LF, Schefler AC, Cassoux N, Hadijistilianou D, Berry JL, et al. Risk of extraocular extension in eye with retinoblastoma receiving intravitreous chemotherapy. JAMA Ophthalmol. 2017;135(12):1426-1429.
• Berry JL, Lewis L, Le BA, Green S, Kim JW, Jubran R. Lack of correlation between age at diagnosis and RB1 mutations for unilateral retinoblastoma: the importance of genetic testing. Ophthalmic Genet. 2017;27:1-3.
• Do J, Do B, Berry JL. Optical coherence tomography for diagnosis and management of retinoblastoma. In: Yanoff M, ed. Advances in Ophthalmology and Optometry. Vol 2. Elsevier; 2017:101-2018.
• Mustafi D, Toy B, Berry JL. Evaluating retinal sequelae of radioactive episcleral plaque brachytherapy for medium-sized choroidal melanomas using optical coherence tomography angiography. In: Yanoff M, ed. Advances in Ophthalmology and Optometry. Vol 2. Elsevier; 2017:119-133.
• Berry JL. My view editorial: a whole new world. The Ophthalmologist. December 2017.
• Wong BW, Berry JL. Acute lymphoblastic leukemia relapse presenting as optic nerve infiltration with hemiretinal artery and vein occlusion. JAMA Ophthalmol. 2017;135(1):e164656.
• Patel LG, Kim JW, Berry JL. Iris lesion causing recalcitrant unilateral glaucoma. Clin Med Img Lib. 2017;3:077.
• Abdallah WF, Aziz HA, Palejwala NV, Berry JL. A Case of BDUMP with unknown primary tumor. BAOJ Ophthalmol. 2017;1:3;002.
• Berry JL. Mother’s intuition and cutting-edge treatment save child’s life. AAO Newsletter. December 2017.
• Berry JL. Cobrinik DC, Kim JW. Detection and intraretinal localization of an ‘invisible’ retinoblastoma using optical coherence tomography. Ocul Oncol Pathol. 2016;2(3):148-152.
• Marvasti A, Berry JL, Saber, Kim JW, Huang AH. Anterior segment scleral fluorescein angiography in the evaluation of ciliary body neoplasm: two case reports. Case Rep Ophthalmol. 2016;7(1):30-38.
• Berry JL, Shih G, Moysidis SN, et al. Patterns of subretinal fluid resolution in group D eyes treated with chemoreduction: experience from the Children’s Hospital Los Angeles/University of Southern California. Ophthalmic Genet. 2016;37(4):400-403.
• Bonanomi MT, Berry JL. Retinoblastoma. Oftalmologia Pediatrica. 4th ed. CBO Serie Oftalmologia Brasiliera; 2016.
• Doshi R, Bergman M, Berry JL. Management of IgG4-related sclerosing disease. Clin Case Rep Rev 1. 2016;3(5):1853-1855.
• Zhu D, Berry JL, Ediriwickrema L, et al. Long-term outcomes of group B eyes in patients with retinoblastoma treated with short-course chemoreduction: experience from Children’s Hospital Los Angeles/University of Southern California. Ocul Oncol Pathol. 2015;2(2):105-111.
• Berry JL, Jubran R, Lee, TC, Murphree AL, Lee D, Kim JW. Low-dose chemoreduction for Infants diagnosed with retinoblastoma before 6 months of age. Ocul Oncol Pathol. 2015;1(2):103-110.
• Browne A, Dandapani S, Jenelle R, Stevanovic M, Lee TC, Murphree AL, Kampp TD, Astrahan MA, Kim JW, Berry JL. Outcomes of medium choroidal melanomas treated with Ruthenium brachytherapy guided by 3D pretreatment modeling. Brachytherapy. 2015;14(5):718-725.
• Berry JL, Kim JW, Jenelle R, Astrahan MA. Use of the toric surgical marker to aid in intraoperative plaque placement for the USC Eye Physics plaques to treat uveal melanoma: a new surgical technique. Ophthalmic Surg Lasers Imaging Retina. 2015;46(8):866-870.
• Jacobsen B, Berry JL, Jubran R, Kim JW. Orbital recurrence following aggressive laser treatment for recurrent retinoblastoma. Ocul Oncol Pathol. 2015;2(2):76-79.
• Kim A, George M, Berry JL. Retinopathy from interferon therapy for cutaneous melanoma in a patient with hypertension and diabetes – a case report. US Ophthalmic Review. 2015;8(2).
• Berry JL, Jubran R, Wong KE, Lee TC, Murphree AL, Kim JW. Factors predictive of long-term visual outcomes of group D eyes treated with chemoreduction and low-dose IMRT salvage: The Children’s Hospital Los Angeles Experience. Br J Ophthalmol. 2014;98(8):1061-1065.
• Liu W, Rootman DB, Berry JL, Hwang CJ, Goldberg RA. Methicillin-resistant Staphylococcus aureus Dacryoadenitis. JAMA Ophthalmol. 2014;132(8):993-995.
• Berry JL, Jubran R, Kim JW, et al. Long-term outcomes of group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage. Pediatr Blood Cancer. 2013;60(4):688-693.
• Berry JL, Dandapani SV, Stevanovic M, et al. Outcomes of choroidal melanomas treated with eye physics: a 20-year review. JAMA Ophthalmol. 2013;131(11):1435-1442.
• Berry JL, Cuzzo L, Bababeygy S, Quiros PA. Unmet need for eyeglasses: results from a Los Angeles county hospital survey. Int Ophthalmol. 2012;32(3):245-250.
• Berry JL, Fawzi A.Heritable disorders of the retinal pigmented epithelium and choriocapillaris. In: Wright KW, Strube YJ, eds. Pediatric Ophthalmology and Strabismus. 3rd ed. New York, NY: Oxford University Press; 2012.
• Swamy R, Berry J, Huang A, Vazquez L. Los Angeles County-University of Southern California residents review: cataract surgery with trabecular micro-bypass stent implantation in patients with mild-to-moderate open-angle glaucoma and cataract: two year follow-up. EyeWorld. August 2012.
• Brauner SC, Berry J, Pye J, Lee E, Rhee DJ. Effect of saline conditions on the tensile strength of ophthalmic sutures. Ophthalmic Surg Lasers Imaging. 2011;42(2):148-151.
• Graeber CP, Gobin YP, Marr BP, Dunkel IJ, Brodie SE, Bornfeld N, Char D, Folberg R, Imhof SM, Lin, Berry JL, et al. Histopathologic findings of eyes enucleated after treatment with chemosurgery for retinoblastoma. Open Ophthalmol J. 2011;5:1-5.
• Lee NG, Berry JL, Wang AT, et al. Sonoporation enhances chemotherapeutic efficacy in retinoblastoma cells in vitro. Invest Ophthalmol Vis Sci. 2011;52(6):3868-3873.
• Khaderi K, Arsalaan A, Cornwell R, Berry J. Retinal imaging past and present. Retinal Physician. March/April 2011.
• Maki (Berry) JL, Marr BP, Abramson DH. Diagnosis of retinoblastoma: how good are referring physicians? Ophthalmic Genet. 2009;30(4):199-205.
• Maki (Berry) J, Qualls M, White B, Kleefield S, Crone R. Health impact assessment and short term medical missions: a methods study to evaluate quality of care. BMC Health Services Research. 2008;8:121.
• Maki (Berry) J, Kusakul S, Morley K, et al. The effect of glasses on visual function following cataract surgery in a cataract camp. Br J Ophthalmol. 2008;92:883-887.
• Maki (Berry) JL, Nesti HA, Shetty RK, Rhee DJ. Transcorneal tube extrusion in a child with a Baerveldt glaucoma drainage device. JAAPO. 2007;11(4):395-397.
• Maki (Berry) J, Woodward K. Treating diabetic retinopathy in developing countries: a retina clinic in Zimbabwe. Retinal Physician. January/February 2007.
• Maki (Berry) J. A mission in seeing: a short-term eye camp in rural Namibia. HMI World. November/December 2005.

---

PROFESSIONAL SOCIETY MEMBERSHIPS

• Retina Society | 2021 to Present
• American Ophthalmological Society (AOS), Candidate for Membership | 2019 to Present
• European Ocular Oncology Group (OOG) | 2017 to Present
• American Association of the Ophthalmic Oncologists and Pathologists | 2016 to Present
• WE C Hope/1 RB World | 2015 to Present
• American Eye Study Club | 2014 to Present
• Children’s Oncology Group | 2014 to Present
• Pan American Association of Ophthalmology | 2014 to Present
• Women in Ophthalmology (WIO) | 2012 to Present
• American Society of Cataract and Refractive Surgery (ASCRS) | 2012 to 2016
• California Association of Eye Physicians & Surgeons (CAEPS) | 2011 to Present
• LA Society of Ophthalmology (LASO) | 2011 to Present
• American Academy of Ophthalmology (AAO) | 2009 to Present
• Association for Research in Vision & Ophthalmology (ARVO) | 2009 to Present
• International Society of Ocular Oncology (ISOO) | 2008 to Present

---

HONORS & AWARDS

• Service Award, WIO | 2021
• Remarkable Research Award, Real World Ophthalmology | 2021
• Mentoring Award for Graduate Students, USC Office of the Provost & Center for Excellence in Teaching | 2021
• Best Talk, Hawaiian Retina | 2021
• National Research Mentoring Network Scholar, National Institutes of Health | 2020
• Merit Award, The Saban Research Institute | 2019
• Achievement Award, AAO | 2019
• Secretariat Award, AAO | 2019
• Excellence in Resident Teaching Award, USC Department of Ophthalmology | 2018
• Travel Grant for Research, ARVO | 2018
• Women Leadership Development Program, ARVO | 2018
• Best Paper, Ocular Oncology, AAO | 2017
• Joanne Engle Poster of Distinction Award, WIO | 2014
• Excellence in Resident Teaching Award, USC Department of Ophthalmology | 2013, 2014
• Heed Ophthalmic Foundation Fellow & Award, Society of Heed Fellows | 2013
• Medical Innovation Award, Los Angeles County Department of Public Health | 2012
• Starr Schulman Fellowship, California Association of Eye Physicians & Surgeons | 2012
• Medical Knowledge Award, USC Department of Ophthalmology | 2011
• McCleary Research Award, Center for Eye Research & Education | 2007
• International Initiatives in Research Grant, Harvard Medical School | 2005
• Nevil & Louise Ford Scholar, Harvard Medical School | 2004 to 2008
• Kappa Alpha Theta Foundation Scholarship, Kappa Alpha Theta | 2002
• Elizabeth Cary Agassiz Scholar, Harvard College | 2000 to 2004